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controls in clinical trials
Robert M. Zwolak, Anton N. Sidawy, Roy K. Greenberg, Marc L.
Schermerhorn, Rebecca J. Shackelton, Flora S. Siami
Purpose: The improvement of available endovascular aortic aneurysm
repair (EVAR) devices is critical for the advancement of patient care in
vascular surgery. The goal of this article is to report a highly detailed, closely
monitored, audited, pooled multicenter cohort of open surgical abdominal
aortic aneurysm (AAA) repairs that has potential for use in future EVAR
studies as a control data set.
Methods: Open surgical AAA repair (open) data from four investigational
device exemption clinical aortic endograft trials were tested for poolability,
merged, and analyzed for the intervals of 0 to 30 days and 31 to 365 days.
Results: The data set includes 323 open patients (83% men; mean age, 70
years). Operative mortality at 30 days was 2.8%. The mean age of women
was 3 years older than men, and mortality at 30 days for women was 5.7%
compared with 2.2% for men (P = .18). Operative mortality for patients with
large AAAs (5.5 cm, 3.6%) was not different than for patients with small
aneurysms (<5.5 cm, 2.4%, P = .54). All-cause mortality at 1 year was
6.7%, with significant predictors including age, sex, and renal failure.
Women had 2.6-fold greater 1-year all-cause mortality rate (13.2%) than
men (5.4%, P = .04), but statistical significance was lost after correction
for age. Two additional AAA-related deaths occurred between days 31 and
365, resulting in a 1-year AAA-related mortality of 3.5%.
Conclusion: This data set provides a tightly controlled, thoroughly detailed,
and audited experience that has the potential to serve as an open control
group for future EVAR trials.A randomized, placebo-controlled trial of doxycycline after endoluminal
aneurysm repair
Amy E. Hackmann, Brian G. Rubin, Luis A. Sanchez, Patrick A. Geraghty,
Robert W. Thompson, John A. Curci
Background: The late durability of endovascular aneurysm repair (EVAR) has
been limited by progressive aortic degeneration believed to be mediated by
matrix metalloproteases (MMP). The goal of this study was to evaluate the
effect of a MMP inhibitor, doxycycline, on EVAR.
Methods: Patients undergoing EVAR were randomized to doxycycline (100
mg twice daily) or placebo for 6 months following the procedure. Clinical
data, blood samples, and computed tomography (CT) scans were obtained
preoperatively, postoperatively (blood only), and at 1- and 6-month
follow-up. Forty-four subjects were analyzed based on intention-to-treat.
Results: Plasma MMP-9 decreased significantly below baseline in the doxycy-
cline (N = 20) treated patients at 6 months (16.4%  20.7%, P < .05) while
there was a nonsignificant increase in the placebo (N = 24) group (128.1% 
73.5%). This was primarily related to changes between 1 and 6 months. In
patients with endoleaks at 6 months, plasma MMP-9 increased in 83% of the
placebo treated patients, but in only 14% of the doxycycline treated group
(P< .03). Among endoleak-free patients with AneuRx or Excluder endografts,
doxycycline treatment resulted in greater decreases in maximum aortic dia-
meter than placebo treatment (13.3%  3.3% vs 3.8%  3.0%, P < .05).* Full articles available online at www.jvascsurg.org
1078e5884/$34.00
doi:10.1016/S1078-5884(08)00391-2Furthermore, doxycycline treatment significantly reduced the aortic neck
dilatation at 6 months in Excluder treated patients.
Conclusion: There is evidence of persistent MMP release representing
ongoing aortic degradation after endografting which can be inhibited by doxy-
cycline therapy. In analyses based on the endograft used, treatment with
doxycycline also demonstrated evidence of increased aortic dimensional
stability, a surrogate marker for long-term success of EVAR. Although encour-
aging, these results require confirmation in larger patient populations. Doxy-
cycline should undergo more thorough evaluation as a potential adjuvant
treatment to improve the results of EVAR, particularly in certain subgroups.Catheter-less angiography for endovascular aortic aneurysm repair: A
new application of carbon dioxide as a contrast agent
Enrique Criado, Loay Kabbani, Kyung Cho
Objective: Avoidance of nephrotoxic contrast agents during endovascular
repair of abdominal aortic aneurysms (EVAR) may reduce the incidence of
renal dysfunction following the procedure. Carbon dioxide (CO2) angio-
graphy is a safe alternative to iodinated contrast media vastly under-utilized
by vascular surgeons. We herein describe our experience with a simple
angiographic technique using CO2 for EVAR guidance that does not require
a separate angiographic catheter.
Methods: Eighteen patients underwent EVAR using angiography with CO2
delivered through the endograft sheath. The renal and hypogastric arteries
were localized for endograft deployment exclusively with CO2 in all patients.
Completion angiography was done with CO2 in all patients and an additional
angiogram with iodinated media was done in 13 cases.
Results: All endograft deployments were done successfully with CO2 angio-
graphy injected through the endograft delivery systems and femoral access
sheaths. Additional iodinated media completion angiography did not modify
the procedure in any case. All patients were discharged within two days after
surgery. Therewere no ischemic or systemiccomplications related toCO2admin-
istration. Follow-up CT-scan revealed well positioned endografts with the ex-
pected patent renal and hypogastric arteries in all patients, and no additional
endoleaks. No significant deterioration in renal function occurred in any case.
Conclusion: Carbon dioxide angiography conducted through the endograft
delivery sheath is reliable for endograft deployment, safe, non-toxic and
inexpensive. In addition, it may expedite EVAR by eliminating a number of
angiographic catheter placements and exchanges during the procedure. This
favorable experience warrants further utilization of this technique.Pivotal results of the Medtronic Vascular Talent Thoracic Stent Graft
System: The VALOR Trial
Ronald M. Fairman, Frank Criado, Mark Farber, Christopher Kwolek, Manish
Mehta, Rodney White, Anthony Lee, J. Michael Tuchek
Objective: This report summarizes the 30-day and 12-month results of endo-
vascular treatment using the Medtronic Vascular Talent Thoracic Stent Graft
System (Medtronic Vascular, SantaRosa,Calif) for patientswith thoracic aortic
aneurysms (TAA) who are considered candidates for open surgical repair.
Methods: The study was a prospective, nonrandomized, multicenter, pivotal
trial conducted at 38 sites. Enrollment occurred between December 2003
and June 2005. Standard follow-up interval examinations were prescribed
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results were compared with retrospective open surgical data from three
centers of excellence.
Results: The Evaluation of the Medtronic Vascular Talent Thoracic Stent
Graft System for the Treatment of Thoracic Aortic Aneurysms (VALOR) trial
enrolled 195 patients, and 189 were identified as retrospective open surgical
subjects. Compared with the open surgery group, the VALOR test group had
similar age and sex distributions, but had a smaller TAA size. Patients
received a mean number of 2.7  1.3 stent graft components. The diameters
of 25% of the proximal stent graft components implanted were <26 mm or
>40 mm. Left subclavian artery revascularization was performed before
the initial stent graft procedure in 5.2% of patients. Iliac conduits were used
in 21.1% of patients. In 33.5% of patients, the bare spring segment of the
most proximally implanted device was in zones 1 or 2 of the aortic arch.
In 194 patients (99.5%), vessel access and stent graft deployment were
successful at the intended site. The 30-day VALOR results included perio-
perative mortality, 2.1%; major adverse advents, 41%; incidence of para-
plegia, 1.5%; paraparesis, 7.2%; and stroke, 3.6%. The 12-month VALOR
results included all-cause mortality, 16.1%; aneurysm-related mortality,
3.1%; conversion to open surgery, 0.5%; target aneurysm rupture, 0.5%; stent
graft migration >10 mm, 3.9%; endoleak (12.2%), stent graft patency, 100%;
stable or decreasing aneurysm diameter, 91.5%; and loss of stent graft integ-
rity, four patients. No deployment-related events or perforation of the aorta
by a graft component occurred. The Talent Thoracic Stent Graft showed
statistically superior performance with respect to acute procedural
outcomes (P < .001), 30-day major adverse events (41% vs 84.4%, P <
.001), perioperative mortality (2% vs 8%, P < .01), and 12-month aneu-
rysm-related mortality (3.1% vs 11.6%, P < .002) vs open surgery.
Conclusions: The pivotal VALOR 12-month trial results demonstrate that the
Medtronic Talent Thoracic Stent Graft System is a safe and effective endo-
vascular therapy as an alternative to open surgery in patients with TAA
who were considered candidates for open surgical repair.Suboptimal use of statin therapy in elderly patients with atherosclerosis:
A population-based study
Mohammed Al-Omran, Muhammad M. Mamdani, Thomas F. Lindsay, Magda
Melo, David N. Juurlink, Subodh Verma
Background: Current evidence suggests that statin use plays an important
role in improving adverse cardiovascular outcomes in patients with athero-
sclerosis. However, limited population-based data are available on use of
statin therapy in these patients in Canada. We sought to study trends in sta-
tin use to treat these patients in Ontario during a 10-year period.
Methods: We conducted a population-based cross-sectional time series
analysis between April 1, 1995, and March 31, 2004, using health care data
from Ontario, Canada.
Results: During the study period, 343,154 elderly patients with atheroscle-
rosis were identified. Of these, 235,615 (68.7%) had coronary artery diseases
(CAD), 115,012 (33.5%) had cerebrovascular disease (CVD), and 23,886 (7.0%)
had peripheral arterial disease (PAD). About 46% were women, and mean
patient age was 77.1 (SD, 7.5) years. During the study period, the percentage
of patients treated with a statin in each group increased considerably, from
9.8% to 55.3% in all atherosclerotic patients (P < .01), from 11.8% to 61.2% in
CAD patients (P < .01), from 5.3% to 41.2% in CVD patients (P < .01), and
from 6.8% to 43.3% in PAD patients (P < .01). During the entire study period,
the percentage of statin users was lowest among PAD and CVD patients, fol-
lowed by patients with both a history of PAD and CVD.
Conclusion: The use of statin therapy in elderly patients with symptomatic
atherosclerosis has increased substantially during the past decade, but many
patients remain untreated. The suboptimal use is greatest among patients
with PAD or CVD, or both, and lowest in patients with CAD. Given the height-
ened risk of cardiovascular adverse outcomes in patients with atheroscle-
rosis, these data have important and immediate implications.Efficacy of duplex ultrasound surveillance after infrainguinal vein bypass
may be enhanced by identification of characteristics predictive of graft
stenosis development
Chelsey N. Tinder, Joe P. Chavanpun, Dennis F. Bandyk, Paul A. Armstrong,
Martin R. Back, Brad L. Johnson, Murray L. Shames
Objective: Controversy regarding the efficacy of duplex ultrasound surveil-
lance after infrainguinal vein bypass led to an analysis of patient and bypassgraft characteristics predictive for development of graft stenosis and a deci-
sion of secondary intervention.
Methods: Retrospective analysis of a contemporary, consecutive series of
353 clinically successful infrainguinal vein bypasses performed in 329
patients for critical (n = 284; 80%) or noncritical (n = 69; 20%) limb ischemia
enrolled in a surveillance program to identify and repair duplex-detected
graft stenosis. Variables correlated with graft stenosis and bypass repair
included: procedure indication, conduit type (saphenous vs nonsaphenous
vein; reversed vs nonreversed orientation), prior bypass graft failure, post-
operative ankle-brachial index (ABI) < 0.85, and interpretation of the first
duplex surveillance study as ‘‘normal’’ or ‘‘abnormal’’ based on peak
systolic velocity (PSV) and velocity ratio (Vr) criteria.
Results: Overall, 126 (36%) of the 353 infrainguinal bypasses had 174
secondary interventions (endovascular, 100; surgery, 74) based on duplex
surveillance; resulting in 3-year Kaplan-Meier primary (46%), assisted-
primary (80%), and secondary (81%) patency rates. Characteristics predictive
of duplex-detected stenosis leading to intervention (PSV: 443  94 cm/s; Vr:
8.6  9) were: ‘‘abnormal’’ initial duplex testing indicating moderate (PSV:
180e300 cm/s, Vr: 2e3.5) stenosis (P < .0001), non-single segment saphe-
nous vein conduit (P < .01), warfarin drug therapy (P < .01), and redo bypass
grafting (P < .001). Procedure indication, postoperative ABI level, statin
drug therapy, and vein conduit orientation were not predictive of graft revi-
sion. The natural history of 141 (40%) bypasses with an abnormal first duplex
scan differed from ‘‘normal’’ grafts by more frequent (51% vs 24%, P < .001)
and earlier (7 months vs 11 months) graft revision for severe stenosis and
a lower 3-year assisted primary patency (68% vs 87%; P < .001). In 52 (15%)
limbs, the bypass graft failed and 20 (6%) limbs required amputation.
Conclusions: The efficacy of duplex surveillance after infrainguinal vein
bypass may be enhanced by modifying testing protocols, eg, rigorous surveil-
lance for ‘‘higher risk’’ bypasses, based on the initial duplex scan results and
other characteristics (warfarin therapy, non- single segment saphenous vein
conduit, redo bypass) predictive for stenosis development.Carotid endarterectomy within 2 weeks of minor ischemic stroke: A
prospective study
Enzo Ballotta, Giorgio Meneghetti, Giuseppe Da Giau, Renzo Manara, Marina
Saladini, Claudio Baracchini
Objective: Data frommulticenter symptomatic trials have shown that benefit
from carotid endarterectomy (CEA) was greatest in patients with carotid
disease operatedwithin 2weeks of their last ischemic event.Weprospectively
analyzed the safety and benefit of CEA performed within 2 weeks of a stroke.
Methods: The study involved patients with acute minor stroke admitted to
two stroke units who underwent CEA within 2 weeks of their last ischemic
event, once they were considered neurologically stable. Preoperative workup
included scoring ischemia-related symptoms according to a modified ranking
scale (mRS), carotid duplex scan, transcranial Doppler ultrasound, and head
computed tomography or magnetic resonance imaging. All patients under-
went neurological assessment on admission, 1 day before and 2 days after
CEA, and at discharge. A complete neurological and ultrasound follow-up
was performed at 1, 6, and 12 months after CEA, then yearly. All procedures
were eversion CEA under deep general anesthesia, with selective shunting.
Endpoints were perioperative (30-day) stroke/mortality rate or cerebral
bleeding and long-term stroke recurrence or cerebral hemorrhage.
Results: Between 2000 and 2005, 102 patients with a mRS  2 underwent
CEA within a median 8 days of acute ischemic stroke. Shunting and contra-
lateral carotid occlusion were found significantly correlated. There were
no perioperative strokes or deaths, or cerebral hemorrhage. All patients
were followed up for a mean 34 months (range 1e66) with no recurrent
stroke or cerebral bleeding.
Conclusions: CEA can be performed within 2 weeks of carotid-related
ischemic stroke with no perioperative stroke or cerebral bleeding, prevent-
ing the risk of stroke recurrence.A prospective evaluation of the outcome after small saphenous varicose
vein surgery with one year follow-up
John L. O’Hare, Chantal P. Vandenbroeck, Birgit Whitman, Bruce Campbell,
Brian P. Heather, Jonothan J. Earnshaw
Objective: The aim was to examine the effect of various surgical maneuvers
during standard surgery for small saphenous varicose veins (SSV).
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small saphenous varicose vein surgery. Two-hundred nineteen consecutive
patients (234 legs) with isolated primary or recurrent small saphenous vari-
cose veins undergoing surgery were enrolled in a multicenter study involving
nine vascular centers in the United Kingdom. Operative technique was
determined by individual surgeon preference; clinical and operative details,
including the use of stripping, were recorded. Clinical examination (recur-
rence rates) and duplex imaging (superficial and deep incompetence) were
evaluated at six weeks and one year after surgery.
Results: A total of 204 legs were reviewed at one year; 67 had small saphe-
nous varicose vein stripping, 116 had saphenopopliteal junction (SPJ)disconnection only, and the remainder had miscellaneous procedures. The
incidence of visible recurrent varicosities at one year was lower after SSV
stripping (12 of 67, 18%) than after disconnection only (28 of 116, 24%),
although this did not reach statistical significance. There was no significant
difference in the rate of numbness at one year between those who had SSV
stripping (20 of 71, 28%) and those who had disconnection only (38 of 134,
28%). The rate of SPJ incompetence detected by duplex at one year was
significantly lower in patients who underwent SSV stripping (9 of 67, 13%)
than in those who did not (37 of 115, 32%) (P < .01).
Conclusion: Stripping of the SSV significantly reduced the rate of SPJ incom-
petence after one year without increasing the rate of complications.
